1Schellhorn C. Classification of quinolones by V Adriole[J]. Infection, 1998,26 (1): 64.
2Blondeau JM, Felmingham D. Activity of moxifloxacin against Community RTIs[J].Clin Drug Invest, 1999,18(1): 57-78.
3Garcia-Rodriguez JA,Trujillano l,Fresnadillo MJ, et al. Adam D,Finch R, eds. Moxifloxacin in practice[M]. Oxford: Maxim Medical, 1999.37-48.
4Stass H,Dalhoff A, Kubitza D. Bay 12 8039:study on the food the effect after oral administration of 200 mg SD to healthy volunteers[C]. Lausanne: ECCMID, 1997. 386.
5Stass HDK. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man[J]. J Antimicrob Chemother, 1999,43(Suppl B): S83 - S90.
6Stass H. Moxifloxacin-review of clinical pharmacokinetics.Metabolism and excretion[C]. Denver:6 th New Quinolones Symposium. 1999.
7Stass H,Kubitza D. Interaction profile of moxifloxacin[J]. Drugs,1999,58(Suppl 2) :S265 S266.
8Springsklee M, Reiter C, Meyer J. Safety and tolerability profile of moxifloxacin (MXF) [C]. ECCMID, 1999. 0208.
